By Fineline Cube 
Gate Bioscience announced the close of its oversubscribed USD 65 million Series B financing led by Forbion and joined by new investor Eli Lilly and Company, alongside existing backers Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners. The proceeds will advance Gate’s lead molecular gate programs into the clinic and expand its pipeline across inflammation and other therapeutic areas.
Financing Details
| Item | Detail |
|---|---|
| Company | Gate Bioscience |
| Amount | USD 65 million (oversubscribed) |
| Round | Series B |
| Lead Investor | Forbion |
| New Investor | Eli Lilly and Company |
| Existing Investors | Versant Ventures, a16z Bio + Health, GV, ARCH Venture Partners |
| Use of Proceeds | Advance lead molecular gate programs to IND; expand pipeline in inflammation and neurology |
Technology Profile
- Platform: Molecular gates – oral small molecules that eliminate inflammatory proteins inside cells before secretion
- Mechanism: Targets high‑value, well‑validated proteins in inflammatory and neurological diseases by blocking intracellular processing
- Key Advantages:
- Oral convenience vs. injectable biologics
- Superior efficacy potential by acting pre‑secretion rather than post‑circulation
- Blood‑brain barrier penetration enabling access to disease‑causing proteins in brain disorders
- Pipeline Focus: Lead programs address cytokine‑driven inflammation; expansion into CNS indications underway
Market Impact & Outlook
- Inflammation Market: Global anti‑inflammatory therapeutics projected to reach $150 billion by 2030; molecular gates could capture share in refractory patient subsets.
- Neurology Opportunity: BBB‑crossing platforms address a $50 billion+ unmet need in neurodegenerative diseases where biologics cannot reach intracellular targets.
- Competitive Edge: Preclinical data suggest 2–3× improved potency vs. post‑secretion inhibitors; oral dosing supports patient adherence.
- Runway & Catalysts: Funding provides runway into Q1 2027, enabling IND filings for two programs in H2 2026; Eli Lilly partnership may accelerate global development.
- Valuation Implications: Post‑money valuation estimated at $250–300 million , positioning Gate for a potential crossover round ahead of IPO.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Gate Bioscience’s clinical development timeline, therapeutic potential of molecular gates, and market opportunities. Actual results may differ materially due to risks including preclinical-to-clinical translation, regulatory pathways, and competitive dynamics.-Fineline Info & Tech